Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 31,250 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 31,250 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the transaction, the insider now directly owns 170,237 shares of the company’s stock, valued at $9,494,117.49. The trade was a 15.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total value of $148,924.38.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $54.00 on Thursday. The stock has a market cap of $3.77 billion, a P/E ratio of -14.40 and a beta of -0.19. The company has a fifty day simple moving average of $29.31 and a 200-day simple moving average of $28.51. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in AKRO. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after buying an additional 446 shares in the last quarter. Eastern Bank purchased a new stake in Akero Therapeutics in the third quarter valued at $100,000. Summit Financial Wealth Advisors LLC acquired a new position in Akero Therapeutics in the third quarter valued at $205,000. Victory Capital Management Inc. purchased a new position in shares of Akero Therapeutics during the third quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Akero Therapeutics during the third quarter worth about $265,000.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AKRO shares. Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright lifted their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday. Canaccord Genuity Group increased their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Morgan Stanley boosted their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.57.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.